×
About 9,087 results

ALLMedicine Plaque Psoriasis Center

Research & Reviews  3,745 results

A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis.
https://doi.org/10.1097/MD.0000000000020048
Medicine Charakopoulos E, Spyrou I et. al.

Jun 1st, 2020 - Ustekinumab is a biological agent that inhibits interleukin 12 and 23 and has been approved for the treatment of moderate and severe plaque psoriasis. There have been case reports that raise concerns about its oncogenic potential. We are the first...

Cost per responder for guselkumab versus secukinumab in the United States based on a he...
https://doi.org/10.1080/09546634.2020.1770172
The Journal of Dermatological Treatment; Teeple A, Fitzgerald T

Jun 1st, 2020 - Aims: To estimate cost per response (CPR) in the United States and number-needed-to-treat (NNT) among subjects receiving guselkumab or secukinumab for moderate to severe plaque psoriasis.Materials and methods: Results from ECLIPSE, a double-blind,...

Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from...
https://doi.org/10.1016/j.jaad.2020.05.105
Journal of the American Academy of Dermatology; Blauvelt A, Papp KA et. al.

May 31st, 2020 - Dual neutralization of both interleukin-17A and interleukin-17F with the monoclonal antibody bimekizumab may have greater efficacy in psoriasis than neutralization of interleukin-17A alone. To provide longer-term efficacy and safety data for bimek...

Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Dise...
https://doi.org/10.1093/ibd/izaa128
Inflammatory Bowel Diseases; Pagnini C, Di Paolo MC et. al.

May 26th, 2020 - Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar.|2020|Pagnini C,Di Paolo MC,De Angelis G,Torcolacci F,Milano M,|

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and a...
https://doi.org/10.1093/rheumatology/keaa189
Rheumatology (Oxford, England); Genovese MC, Mysler E et. al.

May 25th, 2020 - The aim of this integrated analysis is to evaluate the long-term safety and tolerability of ixekizumab in adults with psoriasis, PsA and axial SpA. Integrated safety data from 21 clinical trials are presented by indication in patients who received...

see more →

Guidelines  25 results

Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review
https://www.mdpi.com/1422-0067/21/5/1690/htm
International Journal of Molecular Sciences; Kamata M,et al

Feb 29th, 2020 - Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients’ quality of life enormously. It has been recognized not only as a skin disease but as a systemic disease, since it also causes arthriti...

Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052356/
Frontiers in Pharmacology; Gisondi P,et al

Feb 24th, 2020 - Psoriasis is a chronic, systemic immune-mediated disease characterized by development of erythematous, indurated, scaly, pruritic plaques on the skin. Psoriasis is frequently associated to comorbidities, including psoriatic arthritis, cardiovascul...

Comparison of Biologics and Oral Treatments for Plaque Psoriasis
https://jamanetwork.com/journals/jamadermatology/article-abstract/2759772
JAMA Dermatology; Armstrong AW,et al

Feb 4th, 2020 - In a network meta-analysis of 60 clinical trials for short-term efficacy, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline. A meta-analysis o...

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011535.pub3/full
Cochrane Database of Systematic Reviews; Sbidian E,et al

Jan 8th, 2020 - Psoriasis is an immune‐mediated disease for which some people have a genetic predisposition. The condition manifests in inflammatory effects on either the skin or joints, or both, and it has a major impact on quality of life. Although there is cur...

Imaging techniques in the diagnosis and monitoring of psoriasis
https://www.ncbi.nlm.nih.gov/pubmed/31819765
Experimental and Therapeutic Medicine; Grajdeanu IA,et al

Nov 30th, 2019 - Plaque psoriasis is a chronic, immune-mediated disease, which has a multifactorial etiopathogenesis. Practical non-invasive techniques to monitor plaque psoriasis progression and treatment are necessary. Imaging techniques available for psoriasis ...

see more →

Drugs  189 results see all →

Clinicaltrials.gov  4,355 results

A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis.
https://doi.org/10.1097/MD.0000000000020048
Medicine Charakopoulos E, Spyrou I et. al.

Jun 1st, 2020 - Ustekinumab is a biological agent that inhibits interleukin 12 and 23 and has been approved for the treatment of moderate and severe plaque psoriasis. There have been case reports that raise concerns about its oncogenic potential. We are the first...

Cost per responder for guselkumab versus secukinumab in the United States based on a he...
https://doi.org/10.1080/09546634.2020.1770172
The Journal of Dermatological Treatment; Teeple A, Fitzgerald T

Jun 1st, 2020 - Aims: To estimate cost per response (CPR) in the United States and number-needed-to-treat (NNT) among subjects receiving guselkumab or secukinumab for moderate to severe plaque psoriasis.Materials and methods: Results from ECLIPSE, a double-blind,...

Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from...
https://doi.org/10.1016/j.jaad.2020.05.105
Journal of the American Academy of Dermatology; Blauvelt A, Papp KA et. al.

May 31st, 2020 - Dual neutralization of both interleukin-17A and interleukin-17F with the monoclonal antibody bimekizumab may have greater efficacy in psoriasis than neutralization of interleukin-17A alone. To provide longer-term efficacy and safety data for bimek...

FDA Approves Ixekizumab (Taltz) for Nonradiographic Axial Spondyloarthritis
https://www.medscape.com/viewarticle/931543

May 31st, 2020 - The Food and Drug Administration has extended approval of ixekizumab (Taltz) to the treatment of nonradiographic axial spondyloarthritis (nr-axSpA), according to a press release from its manufacturer, Eli Lilly. Specifically, this supplemental bio...

Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Dise...
https://doi.org/10.1093/ibd/izaa128
Inflammatory Bowel Diseases; Pagnini C, Di Paolo MC et. al.

May 26th, 2020 - Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar.|2020|Pagnini C,Di Paolo MC,De Angelis G,Torcolacci F,Milano M,|

see more →

News  771 results

FDA Approves Ixekizumab (Taltz) for Nonradiographic Axial Spondyloarthritis
https://www.medscape.com/viewarticle/931543

May 31st, 2020 - The Food and Drug Administration has extended approval of ixekizumab (Taltz) to the treatment of nonradiographic axial spondyloarthritis (nr-axSpA), according to a press release from its manufacturer, Eli Lilly. Specifically, this supplemental bio...

Fast Five Quiz: Systemic Treatments for Plaque Psoriasis
https://www.medscape.com/viewarticle/929577

May 20th, 2020 - Approximately 125 million people around the world are affected by psoriasis, a chronic, relapsing inflammatory skin disorder. Several clinical variants of psoriasis are recognized, but plaque psoriasis is the most common. Psoriasis is associated w...

Fast Five Quiz: Plaque Psoriasis Presentation and Diagnosis
https://www.medscape.com/viewarticle/929579

May 20th, 2020 - Plaque psoriasis is a chronic inflammatory disease that primarily affects the skin and joints. Globally, approximately 125 million people have psoriasis. Certain medications, infections, skin trauma, obesity, and stress have been recognized as dis...

FDA approves ixekizumab for pediatric plaque psoriasis
https://www.mdedge.com/jcomjournal/article/219818/pediatrics/fda-approves-ixekizumab-pediatric-plaque-psoriasis?channel=325
Christopher Palmer

Mar 30th, 2020 - The Food and Drug Administration has approved ixekizumab for treatment of moderate to severe plaque psoriasis in patients aged 6-17 years, according to an announcement from Lilly. Patients need to be candidates for systemic therapy or phototherapy.

Human Immunodeficiency Virus Infection in a Hepatitis B Virus–Positive Psoriasis Patient Treated With Ustekinumab
https://www.mdedge.com/dermatology/article/218775/psoriasis/human-immunodeficiency-virus-infection-hepatitis-b-virus?channel=44
Lucía Campos Muñoz, MD, Javier Pedraz Muñoz, PhD et. al.

Mar 11th, 2020 - To the Editor: The incidence of psoriasis in human immunodeficiency virus (HIV)–infected patients is similar to the general population, but it usually becomes more severe as immunosuppression increases. Additionally, it tends to be more resistant.

see more →

Patient Education  2 results see all →